학술논문

382TiP - CONTESSA TRIO: A multinational, multicenter, phase II study of tesetaxel plus 3 different PD-(L)1 inhibitors in patients with metastatic triple negative breast cancer (TNBC) and tesetaxel monotherapy in elderly patients with her2- metastatic breast cancer (MBC)
Document Type
Abstract
Source
In Annals of Oncology October 2019 30 Supplement 5:v138-v139
Subject
Language
ISSN
0923-7534